170 related articles for article (PubMed ID: 36354728)
1. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract][Full Text] [Related]
2. Immunocryosurgery is a safe and feasible treatment for basal cell carcinoma and Bowen disease in renal transplant recipients.
Tsironi T; Gaitanis G; Pappas C; Koutlas V; Dounousi E; Bassukas ID
Dermatol Ther; 2022 May; 35(5):e15405. PubMed ID: 35194902
[TBL] [Abstract][Full Text] [Related]
3. Office-based treatment of basal cell carcinoma with immunocryosurgery: feasibility and efficacy.
Nakuçi M; Bassukas ID
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):35-8. PubMed ID: 23836356
[TBL] [Abstract][Full Text] [Related]
4. Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative.
Gaitanis G; Kalogeropoulos CD; Bassukas ID
Dermatology; 2016; 232(1):17-21. PubMed ID: 26583773
[TBL] [Abstract][Full Text] [Related]
5. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application.
Gaitanis G; Nomikos K; Vava E; Alexopoulos EC; Bassukas ID
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1427-31. PubMed ID: 19555364
[TBL] [Abstract][Full Text] [Related]
6. Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up.
Gaitanis G; Bassukas ID
J Geriatr Oncol; 2019 May; 10(3):475-478. PubMed ID: 30219274
[TBL] [Abstract][Full Text] [Related]
7. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
8. Intralesional bevacizumab as in-add adjuvant to immunocryosurgery for locally advanced basal cell carcinoma.
Gaitanis G; Bassukas I
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1117-21. PubMed ID: 25243268
[TBL] [Abstract][Full Text] [Related]
9. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study.
Gaitanis G; Alexopoulos EC; Bassukas ID
Eur J Dermatol; 2011; 21(6):952-8. PubMed ID: 21926038
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the inflammatory cells infiltrating basal cell carcinomas during immunocryosurgery.
Nomikos K; Lampri E; Spyridonos P; Bassukas ID
Arch Dermatol Res; 2019 Aug; 311(6):499-504. PubMed ID: 31115658
[TBL] [Abstract][Full Text] [Related]
11. Application of a burn scar assessment tool for the evaluation of visual scarring following immunocryosurgery for facial basal cell carcinoma.
Gaitanis G; Spyridonos P; Seretis K; Moschovos V; Bassukas ID
Eur J Dermatol; 2022 Nov; 32(6):709-715. PubMed ID: 36856377
[TBL] [Abstract][Full Text] [Related]
12. Interventions for basal cell carcinoma of the skin.
Thomson J; Hogan S; Leonardi-Bee J; Williams HC; Bath-Hextall FJ
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003412. PubMed ID: 33202063
[TBL] [Abstract][Full Text] [Related]
13. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
[TBL] [Abstract][Full Text] [Related]
14. Cryosurgery and curettage-cryosurgery for basal cell carcinomas of the mid-face.
Samain A; Boullié MC; Duval-Modeste AB; Joly P
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1291-6. PubMed ID: 25354233
[TBL] [Abstract][Full Text] [Related]
15. A Review of Immunocryosurgery and a Practical Guide to Its Applications.
Gaitanis G; Bassukas ID
Diseases; 2021 Oct; 9(4):. PubMed ID: 34698134
[TBL] [Abstract][Full Text] [Related]
16. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up.
Mosterd K; Krekels GA; Nieman FH; Ostertag JU; Essers BA; Dirksen CD; Steijlen PM; Vermeulen A; Neumann H; Kelleners-Smeets NW
Lancet Oncol; 2008 Dec; 9(12):1149-56. PubMed ID: 19010733
[TBL] [Abstract][Full Text] [Related]
17. Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma.
Graells J; Ojeda RM; García-Cruz A
Actas Dermosifiliogr; 2014; 105(1):53-9. PubMed ID: 24139468
[TBL] [Abstract][Full Text] [Related]
18. [The recurrence of facial basal cell carcinoma in patients treated at the Head and Neck Surgery Ward and Laryngological Oncology Clinic of the Greater Poland Cancer Centre in the years 2007-2010].
Pazdrowski J; Dańczak-Pazdrowska A; Golusiński P; Szybiak B; Silny W; Golusiński W
Otolaryngol Pol; 2012; 66(3):185-90. PubMed ID: 22748679
[TBL] [Abstract][Full Text] [Related]
19. Real-life data on basal cell carcinoma treatment: Insights on clinicians' therapeutic choices from an institutional hospital registry.
Manoli SM; Moutsoudis A; Papageorgiou C; Lallas K; Rigas HM; Kyrmanidou E; Papadimitriou I; Paschou E; Spyridis I; Gkentsidi T; Sotiriou E; Vakirlis E; Ioannidis D; Apalla Z; Lallas A
Dermatol Ther; 2020 Nov; 33(6):e14414. PubMed ID: 33064345
[TBL] [Abstract][Full Text] [Related]
20. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.
Rodriguez-Vigil T; Vázquez-López F; Perez-Oliva N
J Am Acad Dermatol; 2007 Jan; 56(1):91-5. PubMed ID: 17190625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
